Abstract

To determine the contribution of ADCY5 mutations in cases with genetically undefined benign hereditary chorea (BHC). We studied 18 unrelated cases with BHC (7 familial, 11 sporadic) who were negative for NKX2-1 mutations. The diagnosis of BHC was based on the presence of a childhood-onset movement disorder, predominantly characterized by chorea and no other major neurologic features. ADCY5 analysis was performed by whole-exome sequencing or Sanger sequencing. ADCY5 and NKX2-1 expression during brain development and in the adult human brain was assessed using microarray analysis of postmortem brain tissue. The c.1252C>T; p.R418W mutation was identified in 2 cases (1 familial, 1 sporadic). The familial case inherited the mutation from the affected father, who had a much milder presentation, likely due to low-grade somatic mosaicism. The mutation was de novo in the sporadic case. The clinical presentation of these cases featured nonparoxysmal generalized chorea, as well as dystonia in the most severely affected, but no facial myokymia. We observed significant progression of symptoms in ADCY5 mutation carriers, in contrast to BHC secondary to NKX2-1 mutations. The difference in the clinical course is mirrored by the brain expression data, showing increasing ADCY5 expression in the striatum during brain development, whereas NKX2-1 shows an opposite trend. Our study identifies mutations in ADCY5, the gene previously linked to familial dyskinesia with facial myokymia, as a cause of familial and sporadic BHC. ADCY5 genetic analysis should be performed in cases with a benign choreiform movement disorder even in the absence of facial myokymia.

Highlights

  • Analysis by whole-exome sequencing (WES) or Sanger sequencing of the adenylate cyclase 5 gene (ADCY5) coding sequence revealed 4 different heterozygous mutations

  • After the identification of ADCY5 as the responsible gene in the original Familial dyskinesia and facial myokymia (FDFM) pedigree, the same group described a second pathogenic missense variant in ADCY5 (c.1252C.T; p.R418W), which occurred de novo in 2 unrelated individuals with a sporadic complex hyperkinetic movement disorder.[16]

  • We report here the results of the ADCY5 mutational analysis in a cohort of NKX2-1–negative sporadic and familial cases with a benign hereditary chorea (BHC)-like presentation

Read more

Summary

Methods

We studied 18 unrelated cases with BHC (7 familial, 11 sporadic) who were negative for NKX2-1 mutations. The diagnosis of BHC was based on the presence of a childhood-onset movement disorder, predominantly characterized by chorea and no other major neurologic features. All cases included in this study were evaluated in the Movement Disorder Center of the National Hospital for Neurology and Neurosurgery, Queen Square, London. We studied 18 consecutive unrelated cases, including 7 with an autosomal dominant family history and 11 sporadic. BHC was clinically diagnosed based on the presence of a movement disorder, with onset before the age of 20 years, predominantly characterized by chorea in the absence of other major neurologic features (i.e., cognitive decline, ataxia, spasticity, or peripheral neuropathy). Medical history was negative for toxin exposure and drugs known to cause chorea

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call